DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for osteopetrosis — screening already-approved drugs against its 18-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleOsteopetrosis maps to a 18-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for osteopetrosis is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
carbonic anhydrase 2 (CA2) — CA2 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet hydroxymercurydrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 3K34 · 0.9 Å · ligand 4-(HYDROXYMERCURY)BENZOIC ACID (HGB). Experimental structure, not a prediction.
What the evidence adds up to
Osteopetrosis is a group of rare metabolic bone diseases defined by impaired osteoclast activity or development, leading to high bone mineral density. The 2017 consensus guidelines from the Osteopetrosis Working Group, developed using a modified Delphi method, state that for noninfantile forms of the disease there is no effective treatment. The guidelines recommend against using high-dose calcitriol and instead advise symptom-based supportive therapy for complications such as cranial nerve impingement, anaemia, leukopenia, and dental disease. The authors note that the scarcity of published studies on osteopetrosis reduces the ability to develop evidence-based guidelines.
Existing guidelines focus on treating severe infantile forms with haematopoietic cell transplantation (HCT), but this is not the standard of care for less severe forms. A 1998 review describes osteopetrosis as a heterogeneous group of congenital bone disorders with a primary reduction in osteoclast-mediated bone resorption. The molecular basis for the disease has been determined in some animal mutations, but little is known concerning the aetiology of most forms in humans. That review discusses how experimental studies in animal models led to the use of bone marrow transplantation and other strategies to treat osteopetrosis in humans, and notes that information from these studies may shed light on broader skeletal diseases such as osteoporosis.
A 2013 commentary on a case series of eleven children with neurological manifestations of osteopetrosis states that the information presented in the original manuscript is classically acceptable but warns that there are delicate points to be reminded of so that readers might not be misled. No specific numbers for survival or response rates are given in any of these abstracts. What remains missing is a clear molecular understanding of most human forms of the disease, adequate published studies to support evidence-based guidelines, and any proven pharmacological treatment for noninfantile osteopetrosis beyond supportive care.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
The Journal of Clinical Endocrinology & Metabolism · 2017 · 241 citations · open access
Diagnosis and Management of Osteopetrosis: Consensus Guidelines From the Osteopetrosis Working Group
AbstractBackground: Osteopetrosis encompasses a group of rare metabolic bone diseases characterized by impaired osteoclast activity or development, resulting in high bone mineral density. Existing guidelines focus on treatment of the severe infantile forms with hematopoietic cell transplantation (HCT) but do not address the management of patients with less severe forms for whom HCT is not the standard of care. Therefore, our objective was to develop expert consensus guidelines for the management of these patients. Methods: A modified Delphi method was used to build consensus among participants of the Osteopetrosis Working Group, with responses to an anonymous online survey used to identify areas of agreement and conflict and develop a follow-up survey. The strength of recommendations and quality of evidence was graded using the Grading of Recommendations Assessment, Development and Evaluation system. Results: Consensus was found in the areas of diagnosis, monitoring, and treatment. We recommend relying on characteristic radiographic findings to make the diagnosis and found that genetic testing adds important information by identifying mutations associated with unique disease complications. We recommend ongoing monitoring for changes in mineral metabolism and other complications, including cranial nerve impingement, anemia, leukopenia, and dental disease. We suggest that calcitriol should not be used in high doses and instead recommend symptom-based supportive therapy for disease complications because noninfantile osteopetrosis has no effective treatment. Conclusions: Scarcity of published studies on osteopetrosis reduce the ability to develop evidence-based guidelines for the management of these patients. Expert opinion-based guidelines for this rare condition are nevertheless important to enable improved care.
AbstractOsteopetrosis describes a heterogeneous group of congenital bone disorders characterized by a generalized increase in skeletal mass resulting from a primary reduction in osteoclast-mediated bone resorption. The pathogenetic heterogeneity is due to differences in the mutated gene that adversely affect the development or activation of the osteoclast. There are numerous naturally occurring and induced osteopetrotic mutations in animals; likewise, children afflicted with this disease also fall into various subgroups. The molecular basis for the disease has been determined in some animal mutations, but little is known concerning the etiology of osteopetrosis in most forms in humans. This review will focus on the genetic defects associated with osteopetrosis that have been identified to date and will demonstrate how experimental studies in animal models of osteopetrosis have led to the use of bone marrow transplantation and other alternative strategies to treat osteopetrosis in humans. The clinical outcomes of these therapeutic strategies and potential therapies for use in the future will be discussed. From this review it should become evident that studies of osteopetrosis in animals will continue to identify the molecular causes for other forms of the disease and to provide information that will help develop new strategies for treatment. In addition, the information gained from these experimental studies is likely to shed additional light on osteoclast biology as well as on broader aspects of skeletal diseases such as inflammation-mediated bone loss and osteoporosis.
Archives of Neuroscience · 2013 · 0 citations · open access
Commentary on “Neurological Manifestations as Presenting Feature of Osteopetrosis in Children: A Review of Eleven Cases”
Abstract: I read with interest the manuscript by Saidinia S et al. (1) about the neuro-manifestations of osteopetrosis. In these communications, the authors have succeeded in forwarding a well-developed discussion of different aspects of the illness and presented their experience with cases, referred to their Neurosurgical department and treated surgically by their group. Even though the information transferred by the authors is classically acceptable but there are delicate points to be reminded so that the readers might not be misled.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
